FDA unanimously shuts down Nektar’s opioid painkiller
The US FDA’s advisory committee voted 27-0 against recommending approval of oxycodegol, with Nektar deciding to withdraw its application as a result.
The US FDA’s advisory committee voted 27-0 against recommending approval of oxycodegol, with Nektar deciding to withdraw its application as a result.
Bayer signs five-year, multi-target women’s health collaboration with Evotec, expanding on earlier deal.
PPD reveals revenues almost doubled between 2014 and 2018 in filing to raise $100m from public investors.
PharmaMar set to supply Jazz Pharmaceuticals with cancer drug from two sites under terms of $1bn deal.